John Bassette – Health & Medicine

Cardiome Pharma reviews net lack of $7.4 million in second quarter 2015 Cardiome Pharma Corp. today reported financial outcomes for the second quarter and six months ended June 30, 2015 swollen genitals . Amounts, unless specified in any other case, are expressed in U.S. Dollars and in accordance with generally accepted accounting principles used in the United States of America . Summary Outcomes Cardiome recorded a net loss of $7.4 million for the three months ended June 30, 2015, in comparison to a net lack of $4.2 million for the 90 days ended June 30, 2014.

This is a substantial step of progress in ourcardiovascular strategy. Cordis brings with it a long and proud legacy of cardiovascular innovation. This move highlights our commitment to address a major pain point in healthcare systems through innovative new approaches to the management of physician preference products. This acquisition comes after a sequence of strategic techniques for Cardinal Wellness in the certain areas of cardiology, wound management and orthopedics. We are well-positioned to greatly help clients standardize around mature medical products, while bringing them innovative solutions around source chain management, inventory optimization, and function flow data and equipment to support the most efficient management of the patient, saidGeorge Barrett, chairman and CEO.

Other Entries "specialist":

Random Entries